OncoMatch/Clinical Trials/NCT05914389
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
Is NCT05914389 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Oxaliplatin and Capecitabine for colon neoplasm.
Phase 2RecruitingSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05914389Data as of May 2026
Treatment: Oxaliplatin · Capecitabine · Anti-PD-L1 Monoclonal Antibody · Clostridium butyricum — This study aims to elucidate the regression effects of neoadjuvant chemotherapy combined with immunotherapy and adjuvant therapy in locally advanced MSS colon cancer.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage T1-4N+
Performance status
ASA 0–3
Prior therapy
No prior treatment (treatment-naive required)
Max 0 prior lines
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify